Vaccination in Patients with Autoimmune Rheumatic Diseases

Czech version

Authors: H. Ciferská ¹; J. Vachek ^2,3
Authors‘ workplace: Revmatologický ústav, Praha a Revmatologická klinika 1. LF UK Praha, ředitel ústavu prof. MUDr. Karel Pavelka, DrSc. ¹; Klinika nefrologie 1. LF UK a VFN v Praze, přednosta prof. MUDr. Vladimír Tesař, DrSc., MBA ²; Interní oddělení a hemodialyzační středisko, Klatovská nemocnice a. s., primář MUDr. Jan Vachek ³
Published in: Čes-slov Derm, 99, 2024, No. 4, p. 155-162
Category: Reviews

Overview

Patients with inflammatory autoimmune rheumatic diseases (AIIRD) are exposed to an increased affinity for infections and their complications. The risk of infection increases with the severity of organ involvement in AIIRD and the type and duration of immunosuppressive therapy. Number of relatively common infections can be prevented by vaccination. Vaccination in patients with AIIRD should be properly timed with respect to disease activity and therapy to achieve its most optimal effectiveness. The experience gained from clinical surveillance, retrospective and prospective analyzes of the incidence of infections and vaccination coverage of the population with AIIRD allowed the development of vaccination recommendations under the auspices of EULAR (European Alliance of Rheumatology Associations) published in 2019 and ACR (American Society of Rheumatology) in 2022. These recommendations take into account the unique AIIRD patient population including their therapy. Vaccination can also be carried out during treatment (except for depletion therapy targeting B lymphocytes), however, it is preferred in stabilized disease with lower activity. The timing of vaccination within therapy must be considered where the antibody response may be influenced by the pharmacological properties of the treatment being administered. Vaccination with live vaccines is not recommended in immunosuppressed patients.

Keywords:

vaccination – immunosuppression – biological treatment – JAK inhibitors

Sources

BASS, A. R., CHAKRAVARTY, E., AKL, E. A., BINGHAM, C. O. et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken), 2023,75(3), p. 449– 464.
FINE, P. E. Herd immunity: history, theory, practice. Epidemiol Rev, 1993,15(2), p. 265–302.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 12, 399(10325), p. 629– 655.
FRIEDMAN, M. A., CURTIS, J. R., WINTHROP, K. L. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann. Rheum. Dis., 2021, 80, p. 1255–1265.
FURER, V., RONDAAN, C., HEIJSTEK, M. et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review Informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 2019.
FURER, V., RONDAAN, C., HEIJSTEK, M. W. et al 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 2020,79, p. 39– 52.
GECKIN, B., FÖHSE, F. K. et al. Trained immunity: implications for vaccination. Curr Opin Immunol, 2022, 77, p. 102190.
GOTE, V., BOLLA, P. K., KOMMINENI, N. et al. Comprehensive Review of mRNA Vaccines. Int J Mol Sci. 2023, 31, 24(3), p. 2700.
JOSEFSBERG, J. O., BUCKLAND, B. Vaccine process technology. Biotechnol Bioeng. 2012, 109(6), p. 1443–1460.
KRASSELT, M., IVANOV, J. P., BAERWALD, C. et al. Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic. Rheumatol Int, 2017,37, p. 229– 237.
LUO, W., YIN, Q. B Cell Response to Vaccination. Immunol Invest. 2021, 50(7), p. 780– 801.
MAISONNEUVE, C., BERTHOLET, S., PHILPOTT, D. J., DE GREGORIO, E. Unleashing the potential of NODand Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A, 2014, 26, 111(34), p. 12294–12299.
OHMES, J., COMDÜHR, S., AKBARZADEH, R. et al Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus. Front. Immunol., 2022, 13, p. 1007078.
PAVELKA, K., MOSTER, E., PTÁČKOVÁ, H. Očkování pacientů s revmatickými onemocněními v České republice. Acta 9. Medicinae, 2013, 5, p. 9–12.
PRIMORAC, D., VRDOLJAK, K., BRLEK, P. et al. Adaptive Immune Responses and Immunity to SARS-CoV-2. Front Immunol., 2022, 4, 13, p. 848582.
RONDAAN, C., FURER, V., HEIJSTEK, M. W. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 9, 5(2), p. e001035.
ULMER, J. B., VALLEY, U., RAPPUOLI, R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol. Nov, 24(11), p. 1377–1383.
VERANI, J. R., BAQUI, A. H., BROOME, CV. et al Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine, 2017, 35(25), p. 3295–3302.
ZAREIAN, N., APRILE, S., CRISTALDI, L., LIGOTTI, M. E., VASTO, S., FARZANEH, F. Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination. Curr Pharm Des., 2019, 25(39), p. 4163–4167.
ZHANG, T., TENG, Z. An SIRVS epidemic model with pulse vaccination strategy. J Theor Biol. 2008, 21, 250(2), p. 375–381.

Podpořeno projektem (Ministerstva zdravotnictví) koncepčního rozvoje výzkumné organizace 023728 (Revmatologický ústav).

Do redakce došlo dne 4. 6. 2024

Adresa pro korespondenci:
MUDr. Hana Ciferská, Ph.D.
Revmatologický ústav
Na Slupi 4
128 50 Praha 2
e-mail: ciferska@revma.cz

Labels

Dermatology & STDs Paediatric dermatology & STDs

Mucous Pemphigoid with Eye Involvement. A Serie of Cases

Multiple Bluish Papules in Daughter and Mother. Minireview

FORTHCOMING EVENTS

Article was published in

Czech-Slovak Dermatology

2024 Issue 4